論文・技術情報追加のお知らせ

①Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS.

薬理学的クラスエフェクトクエリーを用いたリスペリドン安全性プロファイル

対象DB：FAERS

②Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.

ヒト化抗cgrpモノクローナル抗体製剤の安全性プロファイル

対象DB：FAERS

③Consolidated Overview of Notifiable Adverse Events in the U.S. President's Emergency Plan for AIDS Relief's Voluntary Medical Male Circumcision Program Through 2020.

アフリカ諸国男性割礼プログラム後の有害事象サーベイランス

対象DB：NAERS

④Linezolid and the risk of QT interval prolongation: A Pharmacovigilance Study of the Food and Drug Administration Adverse Event Reporting System.

リネゾリドと QT 間隔延長のファーマコビジランス研究

対象DB：FAERS

⑤Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database.

抗骨吸収剤による顎骨壊死のリアルワールドスタディ

対象DB：FAERS

⑥Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.

セマグルチドに関連する胃腸の有害事象ファーマコビジランス研究

対象DB：FAERS

⑦Skin cancer signal associated with phosphodiesterase inhibitors: gaining insight through the FDA pharmacovigilance database.

ホスホジエステラーゼ阻害剤に関連した皮膚癌のシグナル調査

対象DB：FAERS

⑧Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience.

LarebにおけるCOVID-19ワクチンの安全性サーベイランスの最適化研究

対象DB：EudraVigilance